Lucid Diagnostics Files Q2 2024 10-Q
Ticker: LUCD · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1799011
Sentiment: neutral
Topics: 10-Q, financials, quarterly-report
TL;DR
Lucid Diagnostics Q2 10-Q filed. Financials and operations detailed.
AI Summary
Lucid Diagnostics Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and operational updates for the second quarter. Key financial data and disclosures relevant to investors are presented, including balance sheet items and statements of operations.
Why It Matters
This filing provides crucial financial and operational insights into Lucid Diagnostics' performance for the second quarter of 2024, impacting investor decisions.
Risk Assessment
Risk Level: medium — The company is in the medical device sector, which often involves regulatory hurdles and significant R&D investment, contributing to medium risk.
Key Numbers
- 2024-06-30 — Reporting Period End Date (Indicates the end of the financial quarter being reported.)
- 2024-08-12 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2023-12-31 — Previous Fiscal Year End (Provides a comparison point for financial performance.)
Key Players & Entities
- Lucid Diagnostics Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of reporting period
- 20240812 (date) — Filing date
- 360 MADISON AVENUE (address) — Company's business and mail address
- 212 949 4319 (phone_number) — Company's business phone number
FAQ
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the quarter ended June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on August 12, 2024.
What is the company's primary business address?
The company's primary business address is 360 MADISON AVENUE, 25TH FLOOR, NEW YORK, NY 10017.
What is the company's SIC code?
The company's Standard Industrial Classification (SIC) code is 3841, which corresponds to SURGICAL & MEDICAL INSTRUMENTS & APPARATUS.
What are some of the key balance sheet accounts mentioned for March 31, 2024?
Key balance sheet accounts mentioned for March 31, 2024, include Preferred Stock, Common Stock, Additional Paid In Capital, and Retained Earnings.
Filing Stats: 4,563 words · 18 min read · ~15 pages · Grade level 17.8 · Accepted 2024-08-12 08:31:44
Key Financial Figures
- $0.001 — nge on which Registered Common Stock, $0.001 par value per share LUCD The NASDAQ
Filing Documents
- form10-q.htm (10-Q) — 1589KB
- ex10-2.htm (EX-10.2) — 12KB
- ex31-1.htm (EX-31.1) — 18KB
- ex31-2.htm (EX-31.2) — 18KB
- ex32-1.htm (EX-32.1) — 7KB
- ex32-2.htm (EX-32.2) — 7KB
- 0001493152-24-031168.txt ( ) — 7608KB
- lucd-20240630.xsd (EX-101.SCH) — 48KB
- lucd-20240630_cal.xml (EX-101.CAL) — 62KB
- lucd-20240630_def.xml (EX-101.DEF) — 190KB
- lucd-20240630_lab.xml (EX-101.LAB) — 410KB
- lucd-20240630_pre.xml (EX-101.PRE) — 339KB
- form10-q_htm.xml (XML) — 1431KB
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 4.
Controls and Procedures
Controls and Procedures 32
- Other Information
Part II - Other Information Item 1.
Legal Proceedings
Legal Proceedings 33 Item 5. Other Information 33 Item 6. Exhibits 33 Signature 34 Exhibit Index 35 2 Part I - Financial Information Item 1. Financial Statements LUCID DIAGNOSTICS INC. and SUBSIDIARIES (a subsidiary of PAVmed Inc.) CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands except number of shares and per share data - unaudited) June 30, 2024 December 31, 2023 Assets: Current assets: Cash $ 24,920 $ 18,896 Accounts receivable 160 45 Inventory 683 278 Prepaid expenses, deposits, and other current assets 2,184 2,854 Total current assets 27,947 22,073 Fixed assets, net 1,050 1,334 Operating lease right-of-use assets 3,037 1,307 Intangible assets, net 947 1,424 Other assets 1,132 1,132 Total assets $ 34,113 $ 27,270 Liabilities, Preferred Stock and Stockholders' Equity (Deficit) Current liabilities: Accounts payable $ 903 $ 1,146 Accrued expenses and other current liabilities 2,727 3,841 Operating lease liabilities, current portion 884 1,106 Senior Secured Convertible Note - at fair value 11,200 13,950 Due To: PAVmed Inc. - MSA Fee and operating expenses 266 9,339 Total current liabilities 15,980 29,382 Operating lease liabilities, less current portion 2,154 199 Total liabilities 18,134 29,581 Commitments and contingencies - - Stockholders' Equity: Preferred stock, $ 0.001 par value, 20,000,000 shares authorized; Series B and Series B-1 Convertible Preferred Stock, issued and outstanding 55,919 at June 30, 2024 and Series A and Series A-1 Convertible Preferred Stock, shares issued and outstanding 18,625 at December 31, 2023 55,919 18,625 Common stock, $ 0.001 par value, 300,000,000 shares authorized; 49,344,945 and 42,329,864 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively 49 42 Additional paid-in capital 139,865 129,763 Accumulated deficit ( 179,854 ) ( 150,741 ) Total Stockholders' Equi